Li Jinze, Cao Dehong, Peng Lei, Meng Chunyang, Xia Zhongyou, Li Yunxiang, Wei Qiang
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
West China School of Medicine, Sichuan University, Chengdu, China.
Front Oncol. 2021 Dec 21;11:780906. doi: 10.3389/fonc.2021.780906. eCollection 2021.
We performed this study to explore the prognostic value of the pretreatment aspartate transaminase to alanine transaminase (De Ritis) ratio in patients with renal cell carcinoma (RCC).
PubMed, EMBASE, Web of Science, and Cochrane Library were searched to identify all studies. The hazard ratio (HR) with a 95% confidence interval (CI) for overall survival (OS) and cancer-specific survival (CSS) were extracted to evaluate their correlation.
A total of 6,528 patients from 11 studies were included in the pooled analysis. Patients with a higher pretreatment De Ritis ratio had worse OS (HR = 1.41, p < 0.001) and CSS (HR = 1.59, p < 0.001). Subgroup analysis according to ethnicity, disease stage, cutoff value, and sample size revealed that the De Ritis ratio had a significant prognostic value for OS and CSS in all subgroups.
The present study suggests that an elevated pretreatment De Ritis ratio is significantly correlated with worse survival in patients with RCC. The pretreatment De Ritis ratio may serve as a potential prognostic biomarker in patients with RCC, but further studies are warranted to support these results.
我们开展这项研究以探讨肾细胞癌（RCC）患者治疗前天冬氨酸转氨酶与丙氨酸转氨酶比值（德瑞蒂斯比值）的预后价值。
检索PubMed、EMBASE、科学网和考克兰图书馆以识别所有研究。提取总生存（OS）和癌症特异性生存（CSS）的风险比（HR）及95%置信区间（CI）以评估它们之间的相关性。
汇总分析纳入了来自11项研究的共6528例患者。治疗前德瑞蒂斯比值较高的患者OS（HR = 1.41，p < 0.001）和CSS（HR = 1.59，p < 0.001）较差。根据种族、疾病分期、临界值和样本量进行的亚组分析显示，德瑞蒂斯比值在所有亚组中对OS和CSS均具有显著的预后价值。
本研究表明，治疗前德瑞蒂斯比值升高与RCC患者较差的生存显著相关。治疗前德瑞蒂斯比值可能作为RCC患者潜在的预后生物标志物，但需要进一步研究来支持这些结果。
